AbbVie has announced that the European Commission has granted marketing authorizations for its all-oral, short-course, interferon-free treatment of Viekirax (ombitasvir/paritaprevir/ritonavir...
The National Institute for Health and Care Excellence (NICE) recommends Viekirax (ombitasvir + paritaprevir + ritonavir), from AbbVie, with or...
AbbVie announced new data showing high response rates with just eight weeks of Viekirax (ombitasvir/paritaprevir/ritonavir tablets) + Exviera (dasabuvir tablets)...
In final guidance, NICE has recommended Viekirax (ombitasvir–paritaprevir–ritonavir) with or without Exviera (dasabuvir), from Abbvie, as a possible treatment for...
The Japanese Ministry of Health, Labour and Welfare approved AbbVie’s Viekirax (ombitasvir/paritaprevir/ritonavir), as a new interferon-free and ribavirin-free treatment option...
Enanta Pharmaceuticals announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
AbbVie has announced new real-world data with Viekirax (ombitasvir/paritaprevir/ritonavir) plus Exviera (dasabuvir) showing 96 percent of genotype 1 (GT1) hepatitis...
New data from a post-hoc analysis of five completed Phase III clinical trials shows that patients with genotype 1 (GT1)...
The German Institute for Quality and Efficiency in Health Care (IQWiG) has re-examined the added benefit of Exviera plus Viekirax...
The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive...